Pub Date : 2024-01-01DOI: 10.1016/j.joim.2023.12.002
Matthias Huemer , Sandro Graca , Sarah Bitsche , Guenter Hofmann , Mike Armour , Martin Pichler
Background
Many cancer patients seek adjunctive therapies to biomedical cancer treatments at some point of their disease trajectory. While acupuncture is increasingly recommended by leading oncological associations, limited evidence exists concerning the evidence-informed practice and adherence to current guidelines of traditional complementary and integrative medicine (TCIM) practitioners treating cancer patients.
Methods
An international online-survey assessed the demographical data, clinical practice, and sources of information used by TCIM practitioners in Austria, Germany, United States of America, Australia, and New Zealand.
Results
In total, 404 respondents completed the survey, of which 254 (62.9%) treated cancer patients. Most practitioners were acupuncturists and herbalists (57.1%), had (16.8 ± 9.9) years of clinical experience and see a median of 2 (1, 4) cancer patients per week. Breast cancer (61.8%) is the most common cancer type seen in TCIM clinics. Adjunctive TCIM treatments are frequently concurrent with the patient’s cancer specific treatment (39.9%), which is also reflected by the main goal of a TCIM treatment to alleviate side effects (52.4%). However, only 28.0% of the respondents are in contact with the treating oncologist. According to the respondents, pain is most effectively treated using acupuncture, while herbal medicine is best for cancer-related fatigue. TCIM practitioners mostly use certified courses (33.1%) or online databases (28.3%) but often believe that experts are more reliable to inform their practice (37.0%) than research publications (32.7%).
Conclusion
Acupuncturists and herbalists commonly treat cancer patients. Most practitioners use TCIM as an adjunct to biomedicine as supportive care and use it largely in accordance with current oncological guidelines.
Please cite this article as
Huemer M, Graca S, Bitsche S, Hofmann G, Armour M, Pichler M. Mapping the clinical practice of traditional, complementary and integrative medicine in oncology in Western countries: A multinational cross-sectional survey. J Integr Med. 2024; 22(1): 64–71.
{"title":"Mapping the clinical practice of traditional, complementary and integrative medicine in oncology in Western countries: A multinational cross-sectional survey","authors":"Matthias Huemer , Sandro Graca , Sarah Bitsche , Guenter Hofmann , Mike Armour , Martin Pichler","doi":"10.1016/j.joim.2023.12.002","DOIUrl":"10.1016/j.joim.2023.12.002","url":null,"abstract":"<div><h3>Background</h3><p>Many cancer patients seek adjunctive therapies to biomedical cancer treatments at some point of their disease trajectory. While acupuncture is increasingly recommended by leading oncological associations, limited evidence exists concerning the evidence-informed practice and adherence to current guidelines of traditional complementary and integrative medicine (TCIM) practitioners treating cancer patients.</p></div><div><h3>Methods</h3><p>An international online-survey assessed the demographical data, clinical practice, and sources of information used by TCIM practitioners in Austria, Germany, United States of America, Australia, and New Zealand.</p></div><div><h3>Results</h3><p>In total, 404 respondents completed the survey, of which 254 (62.9%) treated cancer patients. Most practitioners were acupuncturists and herbalists (57.1%), had (16.8 ± 9.9) years of clinical experience and see a median of 2 (1, 4) cancer patients per week. Breast cancer (61.8%) is the most common cancer type seen in TCIM clinics. Adjunctive TCIM treatments are frequently concurrent with the patient’s cancer specific treatment (39.9%), which is also reflected by the main goal of a TCIM treatment to alleviate side effects (52.4%). However, only 28.0% of the respondents are in contact with the treating oncologist. According to the respondents, pain is most effectively treated using acupuncture, while herbal medicine is best for cancer-related fatigue. TCIM practitioners mostly use certified courses (33.1%) or online databases (28.3%) but often believe that experts are more reliable to inform their practice (37.0%) than research publications (32.7%).</p></div><div><h3>Conclusion</h3><p>Acupuncturists and herbalists commonly treat cancer patients. Most practitioners use TCIM as an adjunct to biomedicine as supportive care and use it largely in accordance with current oncological guidelines.</p></div><div><h3>Please cite this article as</h3><p>Huemer M, Graca S, Bitsche S, Hofmann G, Armour M, Pichler M. Mapping the clinical practice of traditional, complementary and integrative medicine in oncology in Western countries: A multinational cross-sectional survey. <em>J Integr Med</em>. 2024; 22(1): 64–71.</p></div>","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"22 1","pages":"Pages 64-71"},"PeriodicalIF":4.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2095496423000997/pdfft?md5=f637883b5829283bfea8ef2a3c578818&pid=1-s2.0-S2095496423000997-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139052180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01DOI: 10.1016/j.joim.2024.01.004
Jun-yan He , Xiao-yu Tu , Zi-fei Yin , Hui Mu , Ming-jun Luo , Xing-yu Chen , Wei-bin Cai , Xue Zhao , Can Peng , Fan-fu Fang , Can Lü , Bai Li
<div><h3>Background</h3><p>As one of the most common musculoskeletal ailments, chronic nonspecific low-back pain (CNLBP) causes persistent disability and substantial medical expenses. Epidemiological evidence shows that the incidence rate of CNLBP in young and middle-aged people who are demanded rapidly recovery and social contribution is rising. Recent guidelines indicate a reduced role for medicines in the management of CNLBP.</p></div><div><h3>Objective</h3><p>The present study investigates the short-term effects of cupping and scraping therapy<span> using a medicated balm, compared to nonsteroidal anti-inflammatory drug (NSAID) with a capsaicin plaster, in the treatment of CNLBP.</span></p></div><div><h3>Design, setting, participants and interventions</h3><p>We designed a prospective multicenter randomized clinical trial<span> enrolling patients from January 1, 2022 to December 31, 2022. A total of 156 patients with CNLBP were randomized into two parallel groups. Diclofenac sodium-sustained release tablets were administered orally to participants in the control group for one week while a capsaicin plaster was applied externally. Patients in the test group were treated with cupping and scraping using a medical device and medicated balm.</span></p></div><div><h3>Main outcome measures</h3><p><span>Primary outcome was pain recorded using the visual analogue scale<span> (VAS). Two secondary outcomes were recorded using the Japanese Orthopedic Association low-back pain scale (JOA) and the </span></span>traditional Chinese medicine (TCM) syndrome integral scale (TCMS) as assessment tools.</p></div><div><h3>Results</h3><p>Between baseline and postintervention, all changes in outcome metric scales were statistically significant (<em>P</em><span> < 0.001). Compared to the control group, patients in the test group had a significantly greater treatment effect in all outcome variables, as indicated by lower VAS and TCMS scores and higher JOA scores, after the one-week intervention period (</span><em>P</em><span> < 0.001). Further, according to the findings of multivariate linear regression analysis<span>, the participants’ pain (VAS score) was related to their marital status, age, smoking habits and body mass index. No adverse reactions were reported for any participants in this trial.</span></span></p></div><div><h3>Conclusion</h3><p>The effectiveness of TCM combined with the new physiotherapy tool is superior to that of NSAID combined with topical plasters, regarding to pain intensity, TCM symptoms<span> and quality of life. The TCM plus physiotherapy also showed more stable and long-lasting therapeutic effects.</span></p></div><div><h3>Trial registration</h3><p>This study was registered at Chinese Clinical Trial Registry (ChiCTR2200055655).</p><p>Please cite this article as: He JY, Tu XY, Yin ZF, Mu H, Luo MJ, Chen XY, Cai WB, Zhao X, Peng C, Fang FF, Lü C, Li B. Short-term effects of cupping and scraping therapy for chronic nonspecific low-back
{"title":"Short-term effects of cupping and scraping therapy for chronic nonspecific low-back pain: A prospective, multicenter randomized trial","authors":"Jun-yan He , Xiao-yu Tu , Zi-fei Yin , Hui Mu , Ming-jun Luo , Xing-yu Chen , Wei-bin Cai , Xue Zhao , Can Peng , Fan-fu Fang , Can Lü , Bai Li","doi":"10.1016/j.joim.2024.01.004","DOIUrl":"10.1016/j.joim.2024.01.004","url":null,"abstract":"<div><h3>Background</h3><p>As one of the most common musculoskeletal ailments, chronic nonspecific low-back pain (CNLBP) causes persistent disability and substantial medical expenses. Epidemiological evidence shows that the incidence rate of CNLBP in young and middle-aged people who are demanded rapidly recovery and social contribution is rising. Recent guidelines indicate a reduced role for medicines in the management of CNLBP.</p></div><div><h3>Objective</h3><p>The present study investigates the short-term effects of cupping and scraping therapy<span> using a medicated balm, compared to nonsteroidal anti-inflammatory drug (NSAID) with a capsaicin plaster, in the treatment of CNLBP.</span></p></div><div><h3>Design, setting, participants and interventions</h3><p>We designed a prospective multicenter randomized clinical trial<span> enrolling patients from January 1, 2022 to December 31, 2022. A total of 156 patients with CNLBP were randomized into two parallel groups. Diclofenac sodium-sustained release tablets were administered orally to participants in the control group for one week while a capsaicin plaster was applied externally. Patients in the test group were treated with cupping and scraping using a medical device and medicated balm.</span></p></div><div><h3>Main outcome measures</h3><p><span>Primary outcome was pain recorded using the visual analogue scale<span> (VAS). Two secondary outcomes were recorded using the Japanese Orthopedic Association low-back pain scale (JOA) and the </span></span>traditional Chinese medicine (TCM) syndrome integral scale (TCMS) as assessment tools.</p></div><div><h3>Results</h3><p>Between baseline and postintervention, all changes in outcome metric scales were statistically significant (<em>P</em><span> < 0.001). Compared to the control group, patients in the test group had a significantly greater treatment effect in all outcome variables, as indicated by lower VAS and TCMS scores and higher JOA scores, after the one-week intervention period (</span><em>P</em><span> < 0.001). Further, according to the findings of multivariate linear regression analysis<span>, the participants’ pain (VAS score) was related to their marital status, age, smoking habits and body mass index. No adverse reactions were reported for any participants in this trial.</span></span></p></div><div><h3>Conclusion</h3><p>The effectiveness of TCM combined with the new physiotherapy tool is superior to that of NSAID combined with topical plasters, regarding to pain intensity, TCM symptoms<span> and quality of life. The TCM plus physiotherapy also showed more stable and long-lasting therapeutic effects.</span></p></div><div><h3>Trial registration</h3><p>This study was registered at Chinese Clinical Trial Registry (ChiCTR2200055655).</p><p>Please cite this article as: He JY, Tu XY, Yin ZF, Mu H, Luo MJ, Chen XY, Cai WB, Zhao X, Peng C, Fang FF, Lü C, Li B. Short-term effects of cupping and scraping therapy for chronic nonspecific low-back ","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"22 1","pages":"Pages 39-45"},"PeriodicalIF":4.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139554475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01DOI: 10.1016/j.joim.2024.01.006
Donya Nemati , Niki Munk , Navin Kaushal
<div><h3>Objective</h3><p><span>Patients who experience knee osteoarthritis or chronic knee pain can alleviate their </span>symptoms by performing self-knee massage. Understanding the readiness and types of determinants needed to facilitate self-knee massage is needed to design effective, theory-informed interventions. The primary objective of this study was to apply the transtheoretical model of behavior change to identify how factors, which include the type of knee condition and pain level, predict an individual’s readiness to adopt self-knee massage. The secondary objective employed the capability, opportunity and motivation-behavior (COM-B) model to identify relevant determinants that are predictive of an individual’s readiness to undertake self-knee massage.</p></div><div><h3>Methods</h3><p>An observational study design was used to recruit individuals with knee osteoarthritis (<em>n</em> = 270) and chronic knee pain (<em>n</em><span> = 130). Participants completed an online survey that assessed the transtheoretical model of behavior change stages, COM-B determinants (capability, opportunity and motivation), along with self-administered massage behavior. Multivariate analysis of covariance and structural equation modeling were used to test the primary and secondary objective, respectively.</span></p></div><div><h3>Results</h3><p>Participants who had knee osteoarthritis scored higher on the action stage compared to those with chronic pain (<em>P</em> = 0.003), and those who experienced greater level of pain scored higher in the contemplation (<em>P</em> < 0.001) and action phases (<em>P</em> < 0.001) of performing knee massage compared to those with milder pain. The COM-B structural equation model revealed self-administered knee massage to be predicted by capability (β = 0.31, <em>P</em> = 0.004) and motivation (β = 0.29, <em>P</em> < 0.001), but not opportunity (β = –0.10, <em>P</em> = 0.39). Pain level predicted motivation (β = 0.27, <em>P</em> < 0.001), but not capability (β = 0.09, <em>P</em> = 0.07) or opportunity (β = 0.01, <em>P</em> = 0.83). Tests for mediating effects found that determinants of COM-B (motivation and capability) mediate between pain level and self-administered massage behavior (β = 0.10, <em>P</em> = 0.002).</p></div><div><h3>Conclusion</h3><p>Clinicians and researchers can expect that patients diagnosed with knee osteoarthritis or who have chronic knee pain are ready (action stage) or are considering the behavior (contemplation stage) of self-knee massage. Individuals who report having knee osteoarthritis or chronic knee pain should be coached to develop the skills to perform self-knee massage and helped to develop the motivation to carry out the therapy.</p><p>Please cite this article as: Nemati D, Munk N, Kaushal N. Identifying behavioral determinants and stage of readiness for performing knee massage among individuals with knee osteoarthritis: an observational study. <em>J Integr Med</em>. 2024; 22(1):
{"title":"Identifying behavioral determinants and stage of readiness for performing knee massage among individuals with knee osteoarthritis: An observational study","authors":"Donya Nemati , Niki Munk , Navin Kaushal","doi":"10.1016/j.joim.2024.01.006","DOIUrl":"10.1016/j.joim.2024.01.006","url":null,"abstract":"<div><h3>Objective</h3><p><span>Patients who experience knee osteoarthritis or chronic knee pain can alleviate their </span>symptoms by performing self-knee massage. Understanding the readiness and types of determinants needed to facilitate self-knee massage is needed to design effective, theory-informed interventions. The primary objective of this study was to apply the transtheoretical model of behavior change to identify how factors, which include the type of knee condition and pain level, predict an individual’s readiness to adopt self-knee massage. The secondary objective employed the capability, opportunity and motivation-behavior (COM-B) model to identify relevant determinants that are predictive of an individual’s readiness to undertake self-knee massage.</p></div><div><h3>Methods</h3><p>An observational study design was used to recruit individuals with knee osteoarthritis (<em>n</em> = 270) and chronic knee pain (<em>n</em><span> = 130). Participants completed an online survey that assessed the transtheoretical model of behavior change stages, COM-B determinants (capability, opportunity and motivation), along with self-administered massage behavior. Multivariate analysis of covariance and structural equation modeling were used to test the primary and secondary objective, respectively.</span></p></div><div><h3>Results</h3><p>Participants who had knee osteoarthritis scored higher on the action stage compared to those with chronic pain (<em>P</em> = 0.003), and those who experienced greater level of pain scored higher in the contemplation (<em>P</em> < 0.001) and action phases (<em>P</em> < 0.001) of performing knee massage compared to those with milder pain. The COM-B structural equation model revealed self-administered knee massage to be predicted by capability (β = 0.31, <em>P</em> = 0.004) and motivation (β = 0.29, <em>P</em> < 0.001), but not opportunity (β = –0.10, <em>P</em> = 0.39). Pain level predicted motivation (β = 0.27, <em>P</em> < 0.001), but not capability (β = 0.09, <em>P</em> = 0.07) or opportunity (β = 0.01, <em>P</em> = 0.83). Tests for mediating effects found that determinants of COM-B (motivation and capability) mediate between pain level and self-administered massage behavior (β = 0.10, <em>P</em> = 0.002).</p></div><div><h3>Conclusion</h3><p>Clinicians and researchers can expect that patients diagnosed with knee osteoarthritis or who have chronic knee pain are ready (action stage) or are considering the behavior (contemplation stage) of self-knee massage. Individuals who report having knee osteoarthritis or chronic knee pain should be coached to develop the skills to perform self-knee massage and helped to develop the motivation to carry out the therapy.</p><p>Please cite this article as: Nemati D, Munk N, Kaushal N. Identifying behavioral determinants and stage of readiness for performing knee massage among individuals with knee osteoarthritis: an observational study. <em>J Integr Med</em>. 2024; 22(1): ","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"22 1","pages":"Pages 54-63"},"PeriodicalIF":4.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139554554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01DOI: 10.1016/j.joim.2024.01.007
Rosemary Arnold , Jenifer Murphy-Smith , Chee H. Ng , David Mischoulon , Gerard J. Byrne , Chad A. Bousman , Con Stough , Michael Berk , Jerome Sarris
Objective
The placebo response in depression studies is the change in symptoms amongst those who receive an inactive treatment. Many well-designed randomized controlled trials (RCTs) of depression have a high proportion of placebo responders, with little understanding as to why. The present study assesses characteristics associated with the placebo response in a nutraceutical trial with a large proportion of placebo responders.
Methods
This is a secondary analysis of a nutraceutical depression RCT which identified no overall treatment benefit relative to placebo (n = 69 in placebo group). We investigated participant characteristics such as socio-demographics, clinical features, and recruitment methods, and their association with the placebo response. Monoaminergic genetic polymorphisms were also assessed. Placebo response was measured based on change in Montgomery-Asberg Depression Rating Scale score. The association of these hypothesis-driven variables of interest and the placebo response was examined using linear mixed effects models.
Results
Greater levels of education, particularly pursuing post-high school education, better self-reported general health, marriage/de facto, greater improvement in the first trial week, and more failed antidepressant therapies in the current depressive episode were associated with greater placebo response. An increased placebo response was not found in those recruited via social media nor in those with concomitant antidepressant therapy. Single nucleotide polymorphisms from the tryptophan hydroxylase 1 (TPH1) gene (A779C and A218C) were weakly associated with greater placebo response, although the evidence was attenuated after accounting for multiple comparisons.
Conclusion
This is, to our knowledge, the first study within nutraceutical research for depression to assess the association between participant characteristics and variation in the placebo response. Several variables appeared to predict the placebo response. Such findings may encourage future trial designs which could dampen placebo response, improve assay sensitivity, and allow for treatment effects to be potentially more detectable.
Please cite this article as: Arnold R, Murphy-Smith J, Ng CH, Mischoulon D, Byrne GJ, Bousman CA, Stough C, Berk M, Sarris J. Predictors of the placebo response in a nutraceutical randomized controlled trial for depression. J Integr Med. 2024; 22(1): 46–53.
目标抑郁症研究中的安慰剂反应是指接受非活性治疗者的症状变化。许多精心设计的抑郁症随机对照试验(RCT)中,安慰剂反应者的比例很高,但人们对其原因却知之甚少。本研究评估了在一项安慰剂应答者比例较高的营养保健品试验中与安慰剂应答相关的特征。方法这是一项营养保健品抑郁症随机对照试验的二次分析,该试验发现相对于安慰剂而言,总体治疗效果并不理想(安慰剂组 n = 69)。我们调查了参与者的特征,如社会人口学、临床特征和招募方法,以及它们与安慰剂反应的关系。我们还评估了单胺能基因多态性。安慰剂反应根据蒙哥马利-阿斯伯格抑郁量表评分的变化进行测量。使用线性混合效应模型检验了这些假设驱动的相关变量与安慰剂反应之间的关系。结果受教育程度较高(尤其是接受过高中后教育)、自我报告的一般健康状况较好、已婚/事实婚姻、第一周试验的改善程度较大以及在当前抑郁发作中抗抑郁疗法失败次数较多与安慰剂反应较强相关。通过社交媒体招募的受试者和同时接受抗抑郁治疗的受试者均未发现安慰剂反应增加的情况。色氨酸羟化酶1(TPH1)基因的单核苷酸多态性(A779C和A218C)与安慰剂反应的增加有微弱的相关性,尽管在考虑多重比较后证据有所减弱。有几个变量似乎可以预测安慰剂反应。这些发现可能会鼓励未来的试验设计,从而抑制安慰剂反应,提高检测灵敏度,并使治疗效果更容易被检测到。
{"title":"Predictors of the placebo response in a nutraceutical randomized controlled trial for depression","authors":"Rosemary Arnold , Jenifer Murphy-Smith , Chee H. Ng , David Mischoulon , Gerard J. Byrne , Chad A. Bousman , Con Stough , Michael Berk , Jerome Sarris","doi":"10.1016/j.joim.2024.01.007","DOIUrl":"10.1016/j.joim.2024.01.007","url":null,"abstract":"<div><h3>Objective</h3><p>The placebo response in depression studies is the change in symptoms amongst those who receive an inactive treatment. Many well-designed randomized controlled trials (RCTs) of depression have a high proportion of placebo responders, with little understanding as to why. The present study assesses characteristics associated with the placebo response in a nutraceutical trial with a large proportion of placebo responders.</p></div><div><h3>Methods</h3><p>This is a secondary analysis of a nutraceutical depression RCT which identified no overall treatment benefit relative to placebo (<em>n</em> = 69 in placebo group). We investigated participant characteristics such as socio-demographics, clinical features, and recruitment methods, and their association with the placebo response. Monoaminergic genetic polymorphisms were also assessed. Placebo response was measured based on change in Montgomery-Asberg Depression Rating Scale score. The association of these hypothesis-driven variables of interest and the placebo response was examined using linear mixed effects models.</p></div><div><h3>Results</h3><p>Greater levels of education, particularly pursuing post-high school education, better self-reported general health, marriage/de facto, greater improvement in the first trial week, and more failed antidepressant therapies in the current depressive episode were associated with greater placebo response. An increased placebo response was not found in those recruited via social media nor in those with concomitant antidepressant therapy. Single nucleotide polymorphisms from the tryptophan hydroxylase 1 (<em>TPH1</em>) gene (<em>A779C</em> and <em>A218C</em>) were weakly associated with greater placebo response, although the evidence was attenuated after accounting for multiple comparisons.</p></div><div><h3>Conclusion</h3><p>This is, to our knowledge, the first study within nutraceutical research for depression to assess the association between participant characteristics and variation in the placebo response. Several variables appeared to predict the placebo response. Such findings may encourage future trial designs which could dampen placebo response, improve assay sensitivity, and allow for treatment effects to be potentially more detectable.</p><p>Please cite this article as: Arnold R, Murphy-Smith J, Ng CH, Mischoulon D, Byrne GJ, Bousman CA, Stough C, Berk M, Sarris J. Predictors of the placebo response in a nutraceutical randomized controlled trial for depression. <em>J Integr Med</em>. 2024; 22(1): 46–53.</p></div>","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"22 1","pages":"Pages 46-53"},"PeriodicalIF":4.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2095496424000074/pdfft?md5=c9a4760d210596822c3c4e56242bde72&pid=1-s2.0-S2095496424000074-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139554476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01DOI: 10.1016/j.joim.2024.01.005
Li-ying Liu , Yang Su , Rong-rong Wang , Yuan-yuan Lai , Lei Huang , Yi-ting Li , Xin-yue Tao , Meng-hua Su , Xiao-yan Zheng , Shi-chen Huang , Yong-na Wu , Si-yi Yu , Fan-rong Liang , Jie Yang
Background
Transvaginal oocyte retrieval is frequently followed by adverse events related to anesthesia and the procedure. Some research showed that transcutaneous electrical acupoint stimulation (TEAS) can relieve intraoperative pain and postoperative nausea.
Objective
This study examined whether TEAS can alleviate pain and relieve adverse symptoms after oocyte retrieval.
Design, setting, participants and interventions
Altogether 128 patients were randomly divided into the TEAS group and the mock TEAS group. The two groups received a 30-minute-long TEAS or mock TEAS treatment that began 30 min after oocyte retrieval.
Main outcome measures
The primary outcome was the visual analog scale (VAS) pain score. Secondary outcomes were pressure pain threshold, McGill score, pain rating index (PRI), present pain intensity (PPI), VAS stress score, VAS anxiety score, and postoperative adverse symptoms.
Results
The baseline characteristics of the two groups were comparable (P > 0.05). The VAS pain scores of the TEAS group were lower than those of the mock TEAS group at 60 and 90 min after oocyte retrieval (P < 0.05). The McGill score, PRI and PPI in the TEAS group were significantly lower than those in the control group at 60 min after oocyte retrieval (P < 0.05). However, the two groups had equivalent beneficial effects regarding the negative emotions, such as nervousness and anxiety (P > 0.05). The TEAS group was superior to the mock TEAS group for relieving postoperative adverse symptoms (P < 0.05).
Conclusion
TEAS treatment can relieve postoperative pain and postoperative adverse symptoms for patients undergoing oocyte retrieval.
Please cite this article as: Liu LY, Su Y, Wang RR, Lai YY, Huang L, Li YT, Tao XY, Su MH, Zheng XY, Huang SC, Wu YN, Yu SY, Liang FR, Yang J. Transcutaneous electrical acupoint stimulation benefits postoperative pain relief of oocyte retrieval: A randomized controlled trial. J Integr Med. 2024; 22(1): 32–38.
{"title":"Transcutaneous electrical acupoint stimulation benefits postoperative pain relief of oocyte retrieval: A randomized controlled trial","authors":"Li-ying Liu , Yang Su , Rong-rong Wang , Yuan-yuan Lai , Lei Huang , Yi-ting Li , Xin-yue Tao , Meng-hua Su , Xiao-yan Zheng , Shi-chen Huang , Yong-na Wu , Si-yi Yu , Fan-rong Liang , Jie Yang","doi":"10.1016/j.joim.2024.01.005","DOIUrl":"10.1016/j.joim.2024.01.005","url":null,"abstract":"<div><h3>Background</h3><p>Transvaginal oocyte retrieval is frequently followed by adverse events related to anesthesia and the procedure. Some research showed that transcutaneous electrical acupoint stimulation (TEAS) can relieve intraoperative pain and postoperative nausea.</p></div><div><h3>Objective</h3><p>This study examined whether TEAS can alleviate pain and relieve adverse symptoms after oocyte retrieval.</p></div><div><h3>Design, setting, participants and interventions</h3><p>Altogether 128 patients were randomly divided into the TEAS group and the mock TEAS group. The two groups received a 30-minute-long TEAS or mock TEAS treatment that began 30 min after oocyte retrieval.</p></div><div><h3>Main outcome measures</h3><p>The primary outcome was the visual analog scale (VAS) pain score. Secondary outcomes were pressure pain threshold, McGill score, pain rating index (PRI), present pain intensity (PPI), VAS stress score, VAS anxiety score, and postoperative adverse symptoms.</p></div><div><h3>Results</h3><p>The baseline characteristics of the two groups were comparable (<em>P</em> > 0.05). The VAS pain scores of the TEAS group were lower than those of the mock TEAS group at 60 and 90 min after oocyte retrieval (<em>P</em> < 0.05). The McGill score, PRI and PPI in the TEAS group were significantly lower than those in the control group at 60 min after oocyte retrieval (<em>P</em> < 0.05). However, the two groups had equivalent beneficial effects regarding the negative emotions, such as nervousness and anxiety (<em>P</em> > 0.05). The TEAS group was superior to the mock TEAS group for relieving postoperative adverse symptoms (<em>P</em> < 0.05).</p></div><div><h3>Conclusion</h3><p>TEAS treatment can relieve postoperative pain and postoperative adverse symptoms for patients undergoing oocyte retrieval.</p><p>Please cite this article as: Liu LY, Su Y, Wang RR, Lai YY, Huang L, Li YT, Tao XY, Su MH, Zheng XY, Huang SC, Wu YN, Yu SY, Liang FR, Yang J. Transcutaneous electrical acupoint stimulation benefits postoperative pain relief of oocyte retrieval: A randomized controlled trial. <em>J Integr Med</em>. 2024; 22(1): 32–38.</p></div>","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"22 1","pages":"Pages 32-38"},"PeriodicalIF":4.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139554440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01DOI: 10.1016/j.joim.2024.01.003
Lu-lu Han , Xin Zhang , Hui Zhang , Ting Li , Yi-chen Zhao , Ming-hui Tian , Feng-lei Sun , Bo Feng
<div><h3>Objective</h3><p>Obesity is a global health concern with management strategies encompassing bariatric surgery and anti-obesity drugs; however, concerns regarding complexities and side effects persist, driving research for more effective, low-risk strategies. The promotion of white adipose tissue (WAT) browning has emerged as a promising approach. Moreover, alisol B 23-acetate (AB23A) has demonstrated efficacy in addressing metabolic disorders, suggesting its potential as a therapeutic agent in obesity management. Therefore, in this study, we aimed to investigate the therapeutic potential of AB23A for mitigating obesity by regulating metabolic phenotypes and lipid distribution in mice fed a high-fat diet (HFD).</p></div><div><h3>Methods</h3><p>An obesity mouse model was established by administration of an HFD. Glucose and insulin metabolism were assessed via glucose and insulin tolerance tests. Adipocyte size was determined using hematoxylin and eosin staining. The expression of browning markers in WAT was evaluated using Western blotting and quantitative real-time polymerase chain reaction. Metabolic cage monitoring involved the assessment of various parameters, including food and water intake, energy metabolism, respiratory exchange rates, and physical activity. Moreover, oil red O staining was used to evaluate intracellular lipid accumulation. A bioinformatic analysis tool for identifying the molecular mechanisms of traditional Chinese medicine was used to examine AB23A targets and associated signaling pathways.</p></div><div><h3>Results</h3><p>AB23A administration significantly reduced the weight of obese mice, decreased the mass of inguinal WAT, epididymal WAT, and perirenal adipose tissue, improved glucose and insulin metabolism, and reduced adipocyte size. Moreover, treatment with AB23A promoted the expression of browning markers in WAT, enhanced overall energy metabolism in mice, and had no discernible effect on food intake, water consumption, or physical activity. In 3T3-L1 cells, AB23A inhibited lipid accumulation, and both AB23A and rapamycin inhibited the mammalian target of rapamycin-sterol regulatory element-binding protein-1 (mTOR-SREBP1) signaling pathway. Furthermore, 3-isobutyl-1-methylxanthine, dexamethasone and insulin, at concentrations of 0.25 mmol/L, 0.25 μmol/L and 1 μg/mL, respectively, induced activation of the mTOR-SREBP1 signaling pathway, which was further strengthened by an mTOR activator MHY1485. Notably, MHY1485 reversed the beneficial effects of AB23A in 3T3-L1 cells.</p></div><div><h3>Conclusion</h3><p>AB23A promoted WAT browning by inhibiting the mTOR-SREBP1 signaling pathway, offering a potential strategy to prevent obesity.</p><p>Please cite this article as: Han LL, Zhang X, Zhang H, Li T, Zhao YC, Tian MH, Sun FL, Feng B. Alisol B 23-acetate promotes white adipose tissue browning to mitigate high-fat diet-induced obesity by regulating mTOR-SREBP1 signaling. <em>J Integr Med</em>. 2024; 22(1): 83–92.</
肥胖症是全球关注的健康问题,其管理策略包括减肥手术和抗肥胖药物;然而,人们对其复杂性和副作用的担忧依然存在,这推动了对更有效、低风险策略的研究。促进白色脂肪组织(WAT)褐变已成为一种很有前景的方法。此外,阿利索 B 23-乙酸酯(AB23A)在解决代谢紊乱方面已显示出疗效,这表明它有可能成为肥胖控制的一种治疗剂。因此,在本研究中,我们旨在研究 AB23A 通过调节高脂饮食(HFD)小鼠的代谢表型和脂质分布来减轻肥胖症的治疗潜力。通过葡萄糖和胰岛素耐受试验评估葡萄糖和胰岛素代谢。用苏木精和伊红染色法测定脂肪细胞的大小。使用 Western 印迹法和定量实时聚合酶链反应评估了脂肪细胞中褐变标记物的表达。代谢笼监测涉及各种参数的评估,包括食物和水的摄入量、能量代谢、呼吸交换率和体力活动。此外,还使用油红 O 染色法评估细胞内脂质积累情况。结果AB23A能显著降低肥胖小鼠的体重,减少腹股沟WAT、附睾WAT和肾周脂肪组织的质量,改善葡萄糖和胰岛素代谢,缩小脂肪细胞体积。此外,AB23A 还能促进脂肪细胞褐变标志物的表达,增强小鼠的整体能量代谢,而且对食物摄入量、水消耗量或体力活动没有明显影响。在 3T3-L1 细胞中,AB23A 可抑制脂质积累,AB23A 和雷帕霉素均可抑制哺乳动物雷帕霉素靶标-甾醇调节元件结合蛋白-1(mTOR-SREBP1)信号通路。此外,3-异丁基-1-甲基黄嘌呤、地塞米松和胰岛素(浓度分别为 0.25 mmol/L、0.25 μmol/L 和 1 μg/mL)可诱导激活 mTOR-SREBP1 信号通路,而 mTOR 激活剂 MHY1485 可进一步加强这一作用。结论AB23A通过抑制mTOR-SREBP1信号通路促进脂肪褐变,为预防肥胖提供了一种潜在的策略。
{"title":"Alisol B 23-acetate promotes white adipose tissue browning to mitigate high-fat diet-induced obesity by regulating mTOR-SREBP1 signaling","authors":"Lu-lu Han , Xin Zhang , Hui Zhang , Ting Li , Yi-chen Zhao , Ming-hui Tian , Feng-lei Sun , Bo Feng","doi":"10.1016/j.joim.2024.01.003","DOIUrl":"10.1016/j.joim.2024.01.003","url":null,"abstract":"<div><h3>Objective</h3><p>Obesity is a global health concern with management strategies encompassing bariatric surgery and anti-obesity drugs; however, concerns regarding complexities and side effects persist, driving research for more effective, low-risk strategies. The promotion of white adipose tissue (WAT) browning has emerged as a promising approach. Moreover, alisol B 23-acetate (AB23A) has demonstrated efficacy in addressing metabolic disorders, suggesting its potential as a therapeutic agent in obesity management. Therefore, in this study, we aimed to investigate the therapeutic potential of AB23A for mitigating obesity by regulating metabolic phenotypes and lipid distribution in mice fed a high-fat diet (HFD).</p></div><div><h3>Methods</h3><p>An obesity mouse model was established by administration of an HFD. Glucose and insulin metabolism were assessed via glucose and insulin tolerance tests. Adipocyte size was determined using hematoxylin and eosin staining. The expression of browning markers in WAT was evaluated using Western blotting and quantitative real-time polymerase chain reaction. Metabolic cage monitoring involved the assessment of various parameters, including food and water intake, energy metabolism, respiratory exchange rates, and physical activity. Moreover, oil red O staining was used to evaluate intracellular lipid accumulation. A bioinformatic analysis tool for identifying the molecular mechanisms of traditional Chinese medicine was used to examine AB23A targets and associated signaling pathways.</p></div><div><h3>Results</h3><p>AB23A administration significantly reduced the weight of obese mice, decreased the mass of inguinal WAT, epididymal WAT, and perirenal adipose tissue, improved glucose and insulin metabolism, and reduced adipocyte size. Moreover, treatment with AB23A promoted the expression of browning markers in WAT, enhanced overall energy metabolism in mice, and had no discernible effect on food intake, water consumption, or physical activity. In 3T3-L1 cells, AB23A inhibited lipid accumulation, and both AB23A and rapamycin inhibited the mammalian target of rapamycin-sterol regulatory element-binding protein-1 (mTOR-SREBP1) signaling pathway. Furthermore, 3-isobutyl-1-methylxanthine, dexamethasone and insulin, at concentrations of 0.25 mmol/L, 0.25 μmol/L and 1 μg/mL, respectively, induced activation of the mTOR-SREBP1 signaling pathway, which was further strengthened by an mTOR activator MHY1485. Notably, MHY1485 reversed the beneficial effects of AB23A in 3T3-L1 cells.</p></div><div><h3>Conclusion</h3><p>AB23A promoted WAT browning by inhibiting the mTOR-SREBP1 signaling pathway, offering a potential strategy to prevent obesity.</p><p>Please cite this article as: Han LL, Zhang X, Zhang H, Li T, Zhao YC, Tian MH, Sun FL, Feng B. Alisol B 23-acetate promotes white adipose tissue browning to mitigate high-fat diet-induced obesity by regulating mTOR-SREBP1 signaling. <em>J Integr Med</em>. 2024; 22(1): 83–92.</","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"22 1","pages":"Pages 83-92"},"PeriodicalIF":4.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2095496424000037/pdfft?md5=aa5eacc46ad058398ada8236b7b97dab&pid=1-s2.0-S2095496424000037-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139554766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01DOI: 10.1016/j.joim.2024.01.001
Jing-shun Meng , Yun He , Heng-bin Yang , Li-ping Zhou , Si-yuan Wang , Xi-lin Feng , Omar Yahya Al-shargi , Xiao-min Yu , Li-qing Zhu , Chang-quan Ling
Objective
Melittin and its derivative have been developed to support effective gene delivery systems. Their ability to facilitate endosomal release enhances the delivery of nanoparticle-based gene therapy. Nevertheless, its potential application in the context of viral vectors has not received much attention. Therefore, we would like to optimize the rAAV vector by Melittin analog to improve the transduction efficiency of rAAV in liver cancer cells and explore the mechanism of Melittin analog on rAAV.
Methods
Various melittin-derived peptides were inserted into loop VIII of the capsid protein in recombinant adeno-associated virus vectors. These vectors carrying either gfp or fluc genes were subjected to quantitative polymerase chain reaction assays and transduction assays in human embryonic kidney 293 (HEK293T) cells to investigate the efficiency of vector production and gene delivery. In addition, the ability of a specific p5RHH-rAAV vector to deliver genes was examined through in vitro transduction of different cultured cells and in vivo tail vein administration to C57BL/6 mice. Finally, the intricate details of the vector-mediated transduction mechanisms were explored by using pharmacological inhibitors of every stage of the rAAV2 intracellular life cycle.
Results
A total of 76 melittin-related peptides were identified from existing literature. Among them, CMA-3, p5RHH and aAR3 were found to significantly inhibit transduction of rAAV2 vector crude lysate. The p5RHH-rAAV2 vectors efficiently transduced not only rAAV-potent cell lines but also cell lines previously considered resistant to rAAV. Mechanistically, bafilomycin A1, a vacuolar endosome acidification inhibitor, completely inhibited the transgene expression mediated by the p5RHH-rAAV2 vectors. Most importantly, p5RHH-rAAV8 vectors also increased hepatic transduction in vivo in C57BL/6 mice.
Conclusion
The incorporation of melittin analogs into the rAAV capsids results in a significant improvement in rAAV-mediated transgene expression. While further modifications remain an area of interest, our studies have substantially broadened the pharmacological prospects of melittin in the context of viral vector-mediated gene delivery.
Please cite this article as: Meng J, He Y, Yang H, Zhou L, Wang S, Feng X, Al-shargi OY, Yu X, Zhu L, Ling, C. Melittin analog p5RHH enhances recombinant adeno-associated virus transduction efficiency. J Integr Med. 2024; 22(1): 72–82.
目的 为支持有效的基因递送系统,开发了美利汀及其衍生物。它们促进内体释放的能力增强了基于纳米颗粒的基因治疗的传递。然而,其在病毒载体方面的潜在应用尚未得到广泛关注。因此,我们希望通过美利汀类似物优化 rAAV 载体,以提高 rAAV 在肝癌细胞中的转导效率,并探索美利汀类似物对 rAAV 的作用机制。对这些携带 gfp 或 fluc 基因的载体进行了定量聚合酶链反应检测,并在人胚肾 293(HEK293T)细胞中进行了转导检测,以研究载体生产和基因递送的效率。此外,还通过体外转导不同的培养细胞和体内尾静脉注射 C57BL/6 小鼠,检验了特定 p5RHH-rAAV 载体传递基因的能力。最后,通过使用 rAAV2 细胞内生命周期各阶段的药理抑制剂,探讨了载体介导转导机制的复杂细节。其中,CMA-3、p5RHH 和 aAR3 能显著抑制 rAAV2 载体粗裂解物的转导。p5RHH-rAAV2 载体不仅能有效地转导具有 rAAV 活性的细胞系,还能有效地转导以前被认为对 rAAV 具有抗性的细胞系。从机理上讲,巴佛洛霉素 A1(一种液泡内质体酸化抑制剂)完全抑制了 p5RHH-rAAV2 载体介导的转基因表达。最重要的是,p5RHH-rAAV8 载体还增加了 C57BL/6 小鼠体内的肝转导。我们的研究大大拓宽了美乐汀在病毒载体介导的基因递送中的药理前景:Meng JS, He Y, Yang HB, Zhou LP, Wang SY, Feng XL, Al-shargi OY, Yu XM, Zhu LQ, Ling CQ.美利汀类似物p5RHH可提高重组腺相关病毒的转导效率J Integr Med.2024; Epub ahead of print.
{"title":"Melittin analog p5RHH enhances recombinant adeno-associated virus transduction efficiency","authors":"Jing-shun Meng , Yun He , Heng-bin Yang , Li-ping Zhou , Si-yuan Wang , Xi-lin Feng , Omar Yahya Al-shargi , Xiao-min Yu , Li-qing Zhu , Chang-quan Ling","doi":"10.1016/j.joim.2024.01.001","DOIUrl":"10.1016/j.joim.2024.01.001","url":null,"abstract":"<div><h3>Objective</h3><p><span><span>Melittin<span> and its derivative have been developed to support effective gene delivery systems. Their ability to facilitate endosomal release enhances the delivery of nanoparticle-based gene therapy. Nevertheless, its potential application in the context of viral vectors has not received much attention. Therefore, we would like to optimize the </span></span>rAAV vector<span> by Melittin analog to improve the transduction efficiency of rAAV in liver </span></span>cancer cells and explore the mechanism of Melittin analog on rAAV.</p></div><div><h3>Methods</h3><p><span>Various melittin-derived peptides were inserted into loop VIII of the capsid protein in recombinant adeno-associated virus vectors. These vectors carrying either </span><span><em>gfp</em></span> or <em>fluc</em><span><span> genes were subjected to quantitative polymerase chain reaction assays and transduction assays in human embryonic kidney 293 (HEK293T) cells to investigate the efficiency of vector production and gene delivery. In addition, the ability of a specific p5RHH-rAAV vector to deliver genes was examined through in vitro transduction of different cultured cells and in vivo </span>tail vein<span> administration to C57BL/6 mice. Finally, the intricate details of the vector-mediated transduction mechanisms were explored by using pharmacological inhibitors of every stage of the rAAV2 intracellular life cycle.</span></span></p></div><div><h3>Results</h3><p>A total of 76 melittin-related peptides were identified from existing literature. Among them, CMA-3, p5RHH and aAR3 were found to significantly inhibit transduction of rAAV2 vector crude lysate. The p5RHH-rAAV2 vectors efficiently transduced not only rAAV-potent cell lines but also cell lines previously considered resistant to rAAV. Mechanistically, bafilomycin A1<span>, a vacuolar endosome acidification inhibitor, completely inhibited the transgene expression mediated by the p5RHH-rAAV2 vectors. Most importantly, p5RHH-rAAV8 vectors also increased hepatic transduction in vivo in C57BL/6 mice.</span></p></div><div><h3>Conclusion</h3><p>The incorporation of melittin analogs into the rAAV capsids results in a significant improvement in rAAV-mediated transgene expression. While further modifications remain an area of interest, our studies have substantially broadened the pharmacological prospects of melittin in the context of viral vector-mediated gene delivery.</p><p>Please cite this article as: Meng J, He Y, Yang H, Zhou L, Wang S, Feng X, Al-shargi OY, Yu X, Zhu L, Ling, C. Melittin analog p5RHH enhances recombinant adeno-associated virus transduction efficiency. <em>J Integr Med.</em> 2024; 22(1): 72–82.</p></div>","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"22 1","pages":"Pages 72-82"},"PeriodicalIF":4.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139499619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Poland has a unique history of traditional Chinese medicine (TCM) dating back to the 17th century when Polish missionary Michael (Michał) Boym was a pioneer in the field. In the 20th century, his successor, Professor Zbigniew Garnuszewski, reintroduced acupuncture to medical practice in Poland. However, other methods of TCM and its holistic approach to patient care have not found their place in modern medicine in Poland. At present, the legal status of TCM in Poland remains unregulated, with TCM included in the broad spectrum of complementary and alternative medicine (CAM) practices. Few reports are available on the use of TCM methods among the Polish population. Integrative medicine combines conventional medicine with evidence-based CAM interventions and considers all aspects of a patient’s health, including physical, emotional, mental, social, and environmental factors. An integrative healthcare model that incorporates TCM modalities and lifestyle recommendations as well as a whole person approach may provide a more sustainable solution for the constantly underfinanced Polish healthcare system, which faces challenges of multimorbidity in an aging society and limited access to care. The coronavirus disease 2019 pandemic, war in Ukraine, and ongoing climate crisis have underscored the need to strengthen the resilience of the Polish healthcare system and search for new solutions. A model of care that blends the best of biomedicine and TCM healing approaches may be a better option for both patients and the healthcare system in Poland.
Please cite this article as: Rybicka M, Zhao J, Piotrowicz K, Ptasnik S, Mitka K, Kocot-Kępska M, Hui KK. Promoting whole person health: Exploring the role of traditional Chinese medicine in Polish healthcare. J Integr Med. 2023; 21(6): 509–517.
{"title":"Promoting whole person health: Exploring the role of traditional Chinese medicine in Polish healthcare","authors":"Monika Rybicka , Jing Zhao , Karolina Piotrowicz , Sara Ptasnik , Kamila Mitka , Magdalena Kocot-Kępska , Ka-Kit Hui","doi":"10.1016/j.joim.2023.10.001","DOIUrl":"10.1016/j.joim.2023.10.001","url":null,"abstract":"<div><p>Poland has a unique history of traditional Chinese medicine (TCM) dating back to the 17th century when Polish missionary Michael (Michał) Boym was a pioneer in the field. In the 20th century, his successor, Professor Zbigniew Garnuszewski, reintroduced acupuncture to medical practice in Poland. However, other methods of TCM and its holistic approach to patient care have not found their place in modern medicine in Poland. At present, the legal status of TCM in Poland remains unregulated, with TCM included in the broad spectrum of complementary and alternative medicine (CAM) practices. Few reports are available on the use of TCM methods among the Polish population. Integrative medicine combines conventional medicine with evidence-based CAM interventions and considers all aspects of a patient’s health, including physical, emotional, mental, social, and environmental factors. An integrative healthcare model that incorporates TCM modalities and lifestyle recommendations as well as a whole person approach may provide a more sustainable solution for the constantly underfinanced Polish healthcare system, which faces challenges of multimorbidity in an aging society and limited access to care. The coronavirus disease 2019 pandemic, war in Ukraine, and ongoing climate crisis have underscored the need to strengthen the resilience of the Polish healthcare system and search for new solutions. A model of care that blends the best of biomedicine and TCM healing approaches may be a better option for both patients and the healthcare system in Poland.</p><p>Please cite this article as: Rybicka M, Zhao J, Piotrowicz K, Ptasnik S, Mitka K, Kocot-Kępska M, Hui KK. Promoting whole person health: Exploring the role of traditional Chinese medicine in Polish healthcare. <em>J Integr Med</em>. 2023; 21(6): 509–517.</p></div>","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"21 6","pages":"Pages 509-517"},"PeriodicalIF":4.8,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S209549642300078X/pdfft?md5=086c053321e44bbff6189eac9f60a87a&pid=1-s2.0-S209549642300078X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71482501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-01DOI: 10.1016/j.joim.2023.11.001
Nian Huang , Hai-wei He , Yu-yu He , Wei Gu , Ming-juan Xu , Long Liu
Objective
Xiaotan Sanjie recipe (XTSJ), a Chinese herbal compound medicine, exerts a significant inhibitory effect on gastric cancer (GC) metastasis. This work investigated the mechanism underlying the XTSJ-mediated inhibition of GC metastasis.
Methods
The effect of XTSJ on GC metastasis and the associated mechanism were investigated in vitro, using GC cell lines, and in vivo, using a GC mouse model, by focusing on the expression of Glc-N-Ac-transferase V (GnT-V; encoded by MGAT5).
Results
The migration and invasion ability of GC cells decreased significantly after XTSJ administration, which confirmed the efficacy of XTSJ in treating GC in vitro. XTSJ increased the accumulation of E-cadherin at junctions between GC cells, which was reversed by MGAT5 overexpression. XTSJ administration and MGAT5 knockdown alleviated the structural abnormality of the cell–cell junctions, while MGAT5 overexpression had the opposite effect. MGAT5 knockdown and XTSJ treatment also significantly increased the accumulation of proteins associated with the E-cadherin-mediated adherens junction complex. Furthermore, the expression of MGAT5 was significantly lower in the lungs of BGC-823-MGAT5 + XTSJ mice than in those of BGC-823-MGAT5 + solvent mice, indicating that the ability of gastric tumors to metastasize to the lung was decreased in vivo following XTSJ treatment.
Conclusion
XTSJ prevented GC metastasis by inhibiting the GnT-V-mediated E-cadherin glycosylation and promoting the E-cadherin accumulation at cell–cell junctions.
Please cite this article as: Huang N, He HW, He YY, Gu W, Xu MJ, Liu L. Xiaotan Sanjie recipe, a compound Chinese herbal medicine, inhibits gastric cancer metastasis by regulating GnT-V-mediated E-cadherin glycosylation. J Integr Med. 2023; 21(6): 561–574.
目的中药调痰散结方对胃癌(GC)转移具有明显的抑制作用。本研究探讨了xtsj介导的抑制胃癌转移的机制。方法研究XTSJ对胃癌转移的影响及其机制,分别采用体外胃癌细胞系和体内胃癌小鼠模型,重点研究glc - n - ac -转移酶V (GnT-V;MGAT5编码)。结果给药后胃癌细胞的迁移和侵袭能力明显下降,证实了XTSJ对胃癌的治疗作用。XTSJ增加了GC细胞间连接处E-cadherin的积累,这被MGAT5过表达逆转。XTSJ给药和MGAT5敲低可减轻细胞-细胞连接结构异常,而MGAT5过表达则有相反的作用。MGAT5敲除和XTSJ处理也显著增加了e -cadherin介导的粘附连接复合物相关蛋白的积累。此外,MGAT5在BGC-823-MGAT5 + XTSJ小鼠肺中的表达明显低于BGC-823-MGAT5 +溶剂小鼠,说明XTSJ治疗后体内胃肿瘤向肺转移的能力降低。结论xtsj通过抑制gnt - v介导的E-cadherin糖基化和促进E-cadherin在细胞-细胞连接处的积累来阻止胃癌转移。黄宁,何红伟,何云云,顾伟,徐俊杰,刘磊。复方中药消炎散结方通过调节gnt - v介导的E-cadherin糖基化抑制胃癌转移。中华医学杂志;2009;21(6): 561 - 574。
{"title":"Xiaotan Sanjie recipe, a compound Chinese herbal medicine, inhibits gastric cancer metastasis by regulating GnT-V-mediated E-cadherin glycosylation","authors":"Nian Huang , Hai-wei He , Yu-yu He , Wei Gu , Ming-juan Xu , Long Liu","doi":"10.1016/j.joim.2023.11.001","DOIUrl":"10.1016/j.joim.2023.11.001","url":null,"abstract":"<div><h3>Objective</h3><p>Xiaotan Sanjie recipe (XTSJ), a Chinese herbal compound medicine, exerts a significant inhibitory effect on gastric cancer (GC) metastasis. This work investigated the mechanism underlying the XTSJ-mediated inhibition of GC metastasis.</p></div><div><h3>Methods</h3><p>The effect of XTSJ on GC metastasis and the associated mechanism were investigated <em>in vitro</em><span>, using GC cell lines, and </span><em>in vivo</em>, using a GC mouse model, by focusing on the expression of Glc-N-Ac-transferase V (GnT-V; encoded by <em>MGAT5</em>).</p></div><div><h3>Results</h3><p><span>The migration and invasion ability of GC cells decreased significantly after XTSJ administration, which confirmed the efficacy of XTSJ in treating GC </span><em>in vitro</em>. XTSJ increased the accumulation of E-cadherin at junctions between GC cells, which was reversed by <em>MGAT5</em> overexpression. XTSJ administration and <em>MGAT5</em> knockdown alleviated the structural abnormality of the cell–cell junctions, while <em>MGAT5</em> overexpression had the opposite effect. <em>MGAT5</em><span><span> knockdown and XTSJ treatment also significantly increased the accumulation of proteins associated with the E-cadherin-mediated </span>adherens junction complex. Furthermore, the expression of </span><em>MGAT5</em> was significantly lower in the lungs of BGC-823-<em>MGAT5</em> + XTSJ mice than in those of BGC-823-<em>MGAT5</em> + solvent mice, indicating that the ability of gastric tumors to metastasize to the lung was decreased <em>in vivo</em> following XTSJ treatment.</p></div><div><h3>Conclusion</h3><p>XTSJ prevented GC metastasis by inhibiting the GnT-V-mediated E-cadherin glycosylation and promoting the E-cadherin accumulation at cell–cell junctions.</p><p><span><span>Please cite this article as: Huang N, He HW, He YY, Gu W, Xu MJ, Liu L. Xiaotan Sanjie recipe, a compound Chinese herbal medicine, inhibits gastric </span>cancer metastasis by regulating GnT-V-mediated E-cadherin glycosylation. </span><em>J Integr Med</em>. 2023; 21(6): 561–574.</p></div>","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"21 6","pages":"Pages 561-574"},"PeriodicalIF":4.8,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135510098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-01DOI: 10.1016/j.joim.2023.11.003
Jian-sheng Li , Hai-long Zhang , Wen Guo , Lu Wang , Dong Zhang , Li-min Zhao , Miao Zhou
<div><h3>Background</h3><p>Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is an important occurrence in the natural history of idiopathic pulmonary fibrosis (IPF), associated with high hospitalization rates, high mortality and poor prognosis. At present, there is no effective treatment for AE-IPF. Chinese herbal medicine has some advantages in treating IPF, but its utility in AE-IPF is unclear.</p></div><div><h3>Objective</h3><p>The treatment of AE-IPF with Kangxian Huanji Granule (KXHJ), a compound Chinese herbal medicine, lacks an evidence-based justification. This study explores the efficacy and safety of KXHJ in patients with AE-IPF.</p></div><div><h3>Design, setting, participants and interventions</h3><p>We designed a randomized, double-blind, placebo-controlled, exploratory clinical trial. A total of 80 participants diagnosed with AE-IPF were randomly assigned to receive KXHJ or a matching placebo; the treatment included a 10 g dose, administered twice daily for 4 weeks, in addition to conventional treatment. Participants were followed up for 12 weeks after the treatment.</p></div><div><h3>Main outcome measures</h3><p>The primary endpoints were treatment failure rate and all-cause mortality. Secondary endpoints included the length of hospitalization, overall survival, acute exacerbation rate, intubation rate, the modified British Medical Research Council (mMRC) score, and the St George’s Respiratory Questionnaire for IPF (SGRQ-I) score.</p></div><div><h3>Results</h3><p>The rate of treatment failure at 4 weeks was lower in the intervention group compared to the control group (risk ratio [RR]: 0.22; 95% confidence interval [CI]: 0.051 to 0.965, <em>P</em> = 0.023). There was no significant difference in all-cause mortality at 16 weeks (RR: 0.75; 95% CI: 0.179 to 3.138; <em>P</em> > 0.999) or in the acute exacerbation rate during the 12-week follow-up period (RR: 0.69; 95% CI: 0.334 to 1.434; <em>P</em> = 0.317). The intervention group had a shorter length of hospitalization than the control group (mean difference [MD]: –3.30 days; 95% CI, –6.300 to –0.300; <em>P</em> = 0.032). Significant differences in the mean change from baseline in the mMRC (between-group difference: –0.67; 95% CI: –0.89 to –0.44; <em>P</em> < 0.001) and SGRQ-I score (between-group difference: –10.36; 95% CI: –16.483 to –4.228; <em>P</em> = 0.001) were observed after 4 weeks, and also in the mMRC (between-group difference: –0.67; 95% CI: –0.91 to –0.43; <em>P</em> < 0.001) and SGRQ-I (between-group difference: –10.28; 95% CI, –15.838 to –4.718; <em>P</em> < 0.001) at 16 weeks. The difference in the adverse events was not significant.</p></div><div><h3>Conclusion</h3><p>KXHJ appears to be effective and safe for AE-IPF and can be considered a complementary treatment in patients with AE-IPF. As a preliminary exploratory study, our results provide a basis for further clinical research.</p></div><div><h3>Trial registration</h3><p>Chinese Clinical Tria
{"title":"Efficacy and safety of Kangxian Huanji Granule as adjunctive treatment in acute exacerbation of idiopathic pulmonary fibrosis: An exploratory randomized controlled trial","authors":"Jian-sheng Li , Hai-long Zhang , Wen Guo , Lu Wang , Dong Zhang , Li-min Zhao , Miao Zhou","doi":"10.1016/j.joim.2023.11.003","DOIUrl":"10.1016/j.joim.2023.11.003","url":null,"abstract":"<div><h3>Background</h3><p>Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is an important occurrence in the natural history of idiopathic pulmonary fibrosis (IPF), associated with high hospitalization rates, high mortality and poor prognosis. At present, there is no effective treatment for AE-IPF. Chinese herbal medicine has some advantages in treating IPF, but its utility in AE-IPF is unclear.</p></div><div><h3>Objective</h3><p>The treatment of AE-IPF with Kangxian Huanji Granule (KXHJ), a compound Chinese herbal medicine, lacks an evidence-based justification. This study explores the efficacy and safety of KXHJ in patients with AE-IPF.</p></div><div><h3>Design, setting, participants and interventions</h3><p>We designed a randomized, double-blind, placebo-controlled, exploratory clinical trial. A total of 80 participants diagnosed with AE-IPF were randomly assigned to receive KXHJ or a matching placebo; the treatment included a 10 g dose, administered twice daily for 4 weeks, in addition to conventional treatment. Participants were followed up for 12 weeks after the treatment.</p></div><div><h3>Main outcome measures</h3><p>The primary endpoints were treatment failure rate and all-cause mortality. Secondary endpoints included the length of hospitalization, overall survival, acute exacerbation rate, intubation rate, the modified British Medical Research Council (mMRC) score, and the St George’s Respiratory Questionnaire for IPF (SGRQ-I) score.</p></div><div><h3>Results</h3><p>The rate of treatment failure at 4 weeks was lower in the intervention group compared to the control group (risk ratio [RR]: 0.22; 95% confidence interval [CI]: 0.051 to 0.965, <em>P</em> = 0.023). There was no significant difference in all-cause mortality at 16 weeks (RR: 0.75; 95% CI: 0.179 to 3.138; <em>P</em> > 0.999) or in the acute exacerbation rate during the 12-week follow-up period (RR: 0.69; 95% CI: 0.334 to 1.434; <em>P</em> = 0.317). The intervention group had a shorter length of hospitalization than the control group (mean difference [MD]: –3.30 days; 95% CI, –6.300 to –0.300; <em>P</em> = 0.032). Significant differences in the mean change from baseline in the mMRC (between-group difference: –0.67; 95% CI: –0.89 to –0.44; <em>P</em> < 0.001) and SGRQ-I score (between-group difference: –10.36; 95% CI: –16.483 to –4.228; <em>P</em> = 0.001) were observed after 4 weeks, and also in the mMRC (between-group difference: –0.67; 95% CI: –0.91 to –0.43; <em>P</em> < 0.001) and SGRQ-I (between-group difference: –10.28; 95% CI, –15.838 to –4.718; <em>P</em> < 0.001) at 16 weeks. The difference in the adverse events was not significant.</p></div><div><h3>Conclusion</h3><p>KXHJ appears to be effective and safe for AE-IPF and can be considered a complementary treatment in patients with AE-IPF. As a preliminary exploratory study, our results provide a basis for further clinical research.</p></div><div><h3>Trial registration</h3><p>Chinese Clinical Tria","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"21 6","pages":"Pages 543-549"},"PeriodicalIF":4.8,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2095496423000845/pdfft?md5=8b69c50f6ff985032d54df985795edab&pid=1-s2.0-S2095496423000845-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135515567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}